Pregnant and nursing women. Investigational Product, Dosage, and Mode of Administration: • Cyclophosphamide 50 mg BID (induction and maintenance) • Oxaliplatin 40 mg/m2 IV (induction) • Capecitabine 650 mg/m2 PO BID (maintenance) • 5-FU 400 mg/m2 over 24 hours as a continuous infusion (induction) • Leucovorin 20 mg/m2 IV bolus (induction) • Nab-paclitaxel 125 mg IV (induction and maintenance) • Bevacizu mab 5 mg/kg IV (induction and maintenance) • Avelumab 10 mg/kg IV(induction and maintenance) • SBRT 8 Gy (induction) • ALT -803 10 µg/kg SC (induction and maintenance) • aNK 2 x 109 cells/dose IV (induction and maintenance) • Ad5 [E1-, E2b-]-CEA 5 x 1011 VP/dose SC (induction and maintenance) • GI-4000 RAS vaccine 40 YU (induction and maintenance) Duration of Treatment: • Induction phase: 8 weeks (minimum) to 1 year (maximum) . • Maintenance phase: Up to 1 year.